Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

drug interactions

  • Open Access
    Weakest-Link Dynamics Predict Apparent Antibiotic Interactions in a Model Cross-Feeding Community
    Mechanisms of Action: Physiological Effects
    Weakest-Link Dynamics Predict Apparent Antibiotic Interactions in a Model Cross-Feeding Community

    With the growing global threat of antimicrobial resistance, novel strategies are required for combatting resistant pathogens. Combination therapy, in which multiple drugs are used to treat an infection, has proven highly successful in the treatment of cancer and HIV. However, this practice has proven challenging for the treatment of bacterial infections due to difficulties in selecting the correct combinations and dosages. An additional...

    Elizabeth M. Adamowicz, William R. Harcombe
  • Open Access
    Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
    Pharmacology
    Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects

    Durlobactam (DUR; also known as ETX2514) is a novel β-lactamase inhibitor with broad activity against Ambler class A, C, and D β-lactamases. Addition of DUR to sulbactam (SUL) in vitro restores SUL activity against clinical isolates of Acinetobacter baumannii. The safety and pharmacokinetics (PK) of DUR alone and with SUL and/or imipenem-cilastatin (IMI-CIL)...

    Jason D. Lickliter, Kenneth Lawrence, John O’Donnell, Robin Isaacs
  • Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions
    Minireview
    Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions

    Many antibiotics carry caution stickers that warn against alcohol consumption. Data regarding concurrent use are sparse. An awareness of data that address this common clinical scenario is important so health care professionals can make informed clinical decisions and address questions in an evidence-based manner. The purpose of this systematic review was to determine the evidence behind alcohol warnings issued for many common...

    Kari A. Mergenhagen, Bethany A. Wattengel, Megan K. Skelly, Collin M. Clark, Thomas A. Russo
  • A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment
    Minireview
    A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment

    Tuberculosis (TB) and hepatitis C virus (HCV) infections are both major public health problems. Despite high rates of coinfection, there is scarce literature addressing the convergence of the two diseases. One particularly unexplored area is the potential for simultaneous treatment of TB and HCV which would allow for leveraging an extensive global TB treatment infrastructure to help scale up HCV treatment.

    Russell R. Kempker, Wael A. Alghamdi, Mohammad H. Al-Shaer, Gena Burch, Charles A. Peloquin
  • Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients
    Clinical Therapeutics
    Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients

    Therapeutic drug monitoring (TDM) of moxifloxacin is recommended to improve the response to tuberculosis treatment and reduce acquired drug resistance. Limited sampling strategies (LSSs) are able to reduce the burden of TDM by using a small number of appropriately timed samples to estimate the parameter of interest, the area under the concentration-time curve.

    Simone H. J. van den Elsen, Marieke G. G. Sturkenboom, Onno W. Akkerman, Katerina Manika, Ioannis P. Kioumis, Tjip S. van der Werf, John L. Johnson, Charles Peloquin, Daan J. Touw, Jan-Willem C. Alffenaar
  • <em>In Vitro</em> Evaluation of the Drug Interaction Potential of Doravirine
    Antiviral Agents
    In Vitro Evaluation of the Drug Interaction Potential of Doravirine

    Doravirine is a novel nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 infection. In vitro studies were conducted to assess the potential for drug interactions with doravirine via major drug-metabolizing enzymes and transporters.

    Kelly Bleasby, Kerry L. Fillgrove, Robert Houle, Bing Lu, Jairam Palamanda, Deborah J. Newton, Meihong Lin, Grace Hoyee Chan, Rosa I. Sanchez
  • Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection
    Pharmacology
    Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection

    Artemether-lumefantrine is often coadministered with efavirenz-based antiretroviral therapy for malaria treatment in HIV-infected women during pregnancy. Previous studies showed changes in lumefantrine pharmacokinetics due to interaction with efavirenz in nonpregnant adults.

    Adebanjo Adegbola, Rana Abutaima, Adeniyi Olagunju, Omotade Ijarotimi, Marco Siccardi, Andrew Owen, Julius Soyinka, Oluseye Bolaji
  • Open Access
    Biologic Response Modifiers
    Chemogenomic Profiling of the Fungal Pathogen Candida albicans
    Yaolin Chen, Jaideep Mallick, Alaa Maqnas, Yuan Sun, Baharul I. Choudhury, Pierre Côte, Lan Yan, Ting-jun-hong Ni, Yan Li, Dazhi Zhang, Roberto Rodríguez-Ortiz, Quan-zhen Lv, Yuan-ying Jiang, Malcolm Whiteway
  • Antiviral Agents
    Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis
    Louvina E. van der Laan, Anthony J. Garcia-Prats, H. Simon Schaaf, Tjokosela Tikiso, Lubbe Wiesner, Mine de Kock, Jana Winckler, Jennifer Norman, Helen McIlleron, Paolo Denti, Anneke C. Hesseling
  • Pharmacology
    Flucloxacillin Results in Suboptimal Plasma Voriconazole Concentrations
    Eline W. Muilwijk, Bart G. J. Dekkers, Stefanie S. V. Henriet, Paul E. Verweij, Bregje Witjes, Astrid M. L. Oude Lashof, Geert H. Groeneveld, Johannes van der Hoeven, Jan Willem C. Alffenaar, Frans G. M. Russel, Frank van de Veerdonk, Roger J. M. Brüggemann

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596